Gilead to buy cancer drugmaker Immunomedics in $21 billion deal


A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

David Paul Morris | Bloomberg | Getty Images

Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead’s availability of cancer treatments, the companies announced on Sunday. 

The deal will provide Gilead access to the drug Trodelvy, an FDA-approved treatment for metastatic triple-negative breast cancer.

Gilead said it will acquire Immunomedics for $88 per share in cash. The offer will be funded through about $15 billion in cash on hand and $6 billion in newly issued debt. The transaction is anticipated to close in the fourth quarter of 2020, according to the statement. 

“This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio,” Gilead Chief Executive Daniel O’Day said in a statement. 

“Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat,” O’Day said. “We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments.” 

Immunomedics has a market value of roughly $10 billion after the company’s shares nearly doubled this year. 

This is breaking news. Please check back for updates.



Source link

Discover

Sponsor

Latest

SVE’s limited-edition 2021 Chevy Camaro Yenko S/C rocks 1,050 hp

Specialty Vehicle Engineering (SVE) again proved aftermarket tuners are on the front lines of the horsepower war by announcing a 1,050-horsepower Chevrolet Camaro....

Betting big on these UK stocks doesn’t make sense right now

Employees walk past FTSE AIM share price information displayed on an illuminated rotating cube at the atrium of the London Stock Exchange Group...

Russian state hackers suspected in targeting Biden campaign

Democratic U.S. presidential nominee and former Vice President Joe Biden arrives to discuss the effects on the U.S. economy of the Trump administration's...

IBM earnings Q3 2020

Wired senior staff writer Cade Metz and Arvind Krishna, then senior vice president and director at IBM Research, speak onstage at the Wired...

Yum China shares start trading in Hong Kong in secondary listing

Pedestrians walk past Yum! Brands Shanghai, ChinaBloomberg | GettyShares of Yum China began trading in Hong Kong on Thursday, but lost more...